Zentalis Pharmaceuticals, Inc. (ZNTL)
收市後：
| 前收市價 | 13.00 |
| 開市 | 13.10 |
| 買盤 | 12.49 x 100 |
| 賣出價 | 12.61 x 100 |
| 今日波幅 | 12.57 - 13.46 |
| 52 週波幅 | 9.56 - 31.46 |
| 成交量 | |
| 平均成交量 | 824,401 |
| 市值 | 891.97M |
| Beta 值 (5 年，每月) | 1.73 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -4.47 |
| 業績公佈日 | 2024年5月08日 - 2024年5月13日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 34.40 |
ZacksWall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
The consensus price target hints at a 136.4% upside potential for Zentalis Pharmaceuticals, Inc. (ZNTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ZacksDown -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. (ZNTL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
ZacksWhat Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock
Zentalis Pharmaceuticals, Inc. (ZNTL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
